Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data on new myeloma drugs: how well do they work outside trials?

NCT ID NCT06285318

Knowledge-focused Sponsor: Janssen-Cilag Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This study collects information from about 900 people with relapsed/refractory multiple myeloma who received teclistamab or talquetamab in regular medical practice, not in a clinical trial. Researchers will look at how well the drugs work, how long benefits last, and what side effects occur. The goal is to understand real-world outcomes and safety of these T-cell redirecting therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 900 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population include patients who have initiated the treatment with T-cell redirectors outside of a clinical trial setting.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a documented diagnosis of multiple myeloma * Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts * Received at least one dose of teclistamab/talquetamab * Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements Exclusion Criteria: * To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial * To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial * Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsed refractory multiple myeloma (RRMM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsed refractory multiple myeloma (RRMM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    29 sites in 8 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AOU Careggi

    COMPLETED

    Florence, 50141, Italy

  • Aalborg Sygehus Syd

    RECRUITING

    Aalborg, 9100, Denmark

  • Aarhus Universitetshospital

    COMPLETED

    Aarhus N, 8200, Denmark

  • Ahepa University General Hospital of Thessaloniki

    RECRUITING

    Thessaloniki, 54636, Greece

  • Akershus Universitetssykehus

    RECRUITING

    Oslo, 1478, Norway

  • Alexandra Hospital

    RECRUITING

    Athens, 115 28, Greece

  • Anticancer Hospital of Thessaloniki Theageneio

    RECRUITING

    Thessaloniki, 546 39, Greece

  • Azienda Ospedaliera Universitaria Federico II

    COMPLETED

    Naples, 80131, Italy

  • Azienda Sanitaria Universitaria Giuliano Isontina Ospedale Maggiore

    COMPLETED

    Trieste, 34128, Italy

  • Azienda Sanitaria dell'Alto Adige - Ospedale di Bolzano

    COMPLETED

    Bolzano, 39100, Italy

  • Beacon Hospital

    COMPLETED

    Dublin, D18 AK68, Ireland

  • Bon Secours Hospital

    COMPLETED

    Cork, T12 DV56, Ireland

  • CHRU de Nancy - Hopitaux de Brabois

    COMPLETED

    Vandœuvre-lès-Nancy, 54500, France

  • CHU de Nantes hotel Dieu

    RECRUITING

    Nantes, 44000, France

  • Casa di Cura La Maddalena

    COMPLETED

    Palermo, 90146, Italy

  • Cork University Hospital

    COMPLETED

    Cork, 00000, Ireland

  • G Papanikolaou Hospital of Thessaloniki

    RECRUITING

    Thessaloniki, 570 10, Greece

  • Guys and St Thomas NHS Foundation Trust

    COMPLETED

    London, SE1 9RT, United Kingdom

  • Hadassah Medical Center

    COMPLETED

    Jerusalem, 9112001, Israel

  • Hopital Albert Calmette - CHU Lille

    RECRUITING

    Lille, 59037, France

  • Hopital Saint Louis

    COMPLETED

    Paris, 75475, France

  • Hosp. Alvaro Cunqueiro

    RECRUITING

    Vigo, 36213, Spain

  • Hosp. Clinico Univ. de Valencia

    RECRUITING

    Valencia, 46010, Spain

  • Hosp. Costa Del Sol

    COMPLETED

    Málaga, 29603, Spain

  • Hosp. Ntra. Sra. de Sonsoles

    RECRUITING

    Ávila, 05071, Spain

  • Hosp. Univ. Virgen de Las Nieves

    RECRUITING

    Granada, 18014, Spain

  • Hosp. Univ. de La Paz

    RECRUITING

    Madrid, 28046, Spain

  • Hosp. Univ. de La Princesa

    RECRUITING

    Madrid, 28006, Spain

  • IRCCS Istituto Europeo di Oncologia

    COMPLETED

    Milan, 20252, Italy

  • Institut Paoli Calmettes

    COMPLETED

    Marseille, 13009, France

  • Institut Universitaire du Cancer Toulouse Oncopole

    RECRUITING

    Toulouse, 31100, France

  • Ioannina University Hospital

    RECRUITING

    Ioannina, 45500, Greece

  • Karolinska Universitetssjukhuset

    RECRUITING

    Stockholms, 12559, Sweden

  • Klinikum Chemnitz gGmbH

    COMPLETED

    Chemnitz, 09116, Germany

  • Klinikum Nurnberg Nord

    COMPLETED

    Nuremberg, 90419, Germany

  • Klinikum Region Hannover Klinikum Siloah

    RECRUITING

    Hanover, 30459, Germany

  • Laiko General Hospital of Athens

    RECRUITING

    Athens, 115 27, Greece

  • Länssjukhuset Ryhov

    COMPLETED

    Jönköping, 551 85, Sweden

  • Odense University Hospital

    COMPLETED

    Odense, 5000, Denmark

  • Ospedale A.Perrino di Brindisi

    COMPLETED

    Brindisi, 72100, Italy

  • Ospedale Andrea Tortora Pagani Salerno

    COMPLETED

    Salerno, 84098, Italy

  • Ospedale Ca' Foncello

    COMPLETED

    Treviso, 31100, Italy

  • Ospedale Castelli

    COMPLETED

    Verbania, 28922, Italy

  • Ospedale San Bortolo

    COMPLETED

    Vicenza, 36100, Italy

  • Ospedale Vito Fazzi

    COMPLETED

    Lecce, 73100, Italy

  • Policlinico Sant'Orsola Malpighi

    COMPLETED

    Bologna, 40138, Italy

  • Policlinico di Milano

    COMPLETED

    Milan, 20121, Italy

  • Presidio Ospedaliero Santo Spirito in Sassia

    COMPLETED

    Roma, 65124, Italy

  • Queen Elizabeth Hospital

    RECRUITING

    Birmingham, B15 2GW, United Kingdom

  • Rigshospitalet

    COMPLETED

    Copenhagen, 2100, Denmark

  • Sahlgrenska University Hospital

    RECRUITING

    Gothenburg, 413 45, Sweden

  • Sheba Medical Center

    COMPLETED

    Ramat Gan, 52621, Israel

  • St James Hospital

    COMPLETED

    Dublin, D08 NHY1, Ireland

  • Sygehus Lillebælt, Vejle

    RECRUITING

    Vejle, 7100, Denmark

  • Tel Aviv Sourasky Medical Center

    COMPLETED

    Tel Aviv, 6423906, Israel

  • The Royal Wolverhampton Hospitals NHS Trust - New Cross Hosp

    RECRUITING

    Wolverhampton, WV10 0QP, United Kingdom

  • Uddevalla Hospital

    COMPLETED

    Uddevalla, 451 98, Sweden

  • Uniklinikum Heidelberg 1

    COMPLETED

    Heidelberg, 69120, Germany

  • Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli'

    COMPLETED

    Roma, 00168, Italy

  • Universitatsklinikum Carl Gustav Carus Dresden

    COMPLETED

    Dresden, 01307, Germany

  • University College Hospital

    RECRUITING

    London, NW1 2PG, United Kingdom

  • University Hospital Galway - Ireland

    COMPLETED

    Galway, H91 YR71, Ireland

  • University Hospital Hamburg Eppendorf

    RECRUITING

    Hamburg, 20246, Germany

  • University Hospital Of Larissa

    RECRUITING

    Larissa, 413 34, Greece

  • University Hospital of Alexandroupolis

    RECRUITING

    Alexandroupoli, 68100, Greece

  • University Hospital of Crete, PAGNI

    COMPLETED

    Heraklion, 715 00, Greece

  • Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii

    RECRUITING

    Würzburg, 97080, Germany

  • Vestfold Hospital Trust

    RECRUITING

    Tønsberg, 3103, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.